JS001+Bevacizumab

Phase 1Monoclonal antibody

JS001+Bevacizumab is one of 4 small molecule programs targeting Advanced Malignant Solid Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Malignant Solid TumorsActive, not recruiting

Advanced Malignant Solid TumorsPhase 1

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Advanced Malignant Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Preclinical

1 2

JS207

SShanghai Junshi Bioscience Co., Ltd.

Phase 1

2 3

JS001+Bevacizumab

SShanghai Junshi Bioscience Co., Ltd.

Phase 1

1 4

SCTB41

SSinocelltech Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Advanced Malignant Solid Tumors

NCT06571422

Clinical

Trials by Indication[1]

Advanced Malignant Solid Tumors1 trial

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of WJ47156 Monotherapy and in Combination With Other Anti-Tumor Therapies in Patients With Advanced Malignant Solid Tumors

Active, not recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 1·NCT06571422·59 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for JS001+Bevacizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JS001+Bevacizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JS001+Bevacizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Junshi Bioscience Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 1[1]
Company: SShanghai Junshi Bioscience Co., Ltd.

JS001+Bevacizumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Advanced Malignant Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News